Clinical Trial Update: A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN). [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial assessed whether rosuvastatin reduces the risk of contrast-induced nephropathy in patients undergoing elective angioplasty; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy
• Nephropathy

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: University of Sao Paulo | Conditions: Nephropathy | Phase 4 | Status: COMPLETED